DNDN

A selection of some of the best stories for investors from the Internet, including possible acquisition targets, why BofA got upgraded, good value plays in today's market, and six surging economies to watch.

Dendreon Corp. (DNDN) shares more than doubled in early morning trading, but this may be somewhat misleading. Quick recap: Dendreon yesterday (Tuesday) released detailed results of its innovative prostate cancer drug Provenge. Ahead of the results, the stock first climbed steadily from $22.00 to...

Two weeks ago, Dendreon Corp. (DNDN) reported that its experimental prostate cancer treatment, the therapeutic vaccine Provenge, was significantly successful in prolonging patient survival, but said it would give more details at a later date at the American Urological Association (AUA) Annual...

From a slightly higher core reading from the consumer price index to better-than-expect housing data to the Federal Reserve's Beige Book, which revealed that some of the 12 Fed regions are seeing a deceleration in the slowdown, economic news best described as "less bad" helped buoy stocks today,...

Investors dumped stocks today after a weak retail sales report and lower-than-expected producer price index data showing no inflation. The Dow Jones Industrial Average fell 140 points, or 1.7 percent, to close at 7,918. Citigroup (C) gained more than any of the Dow's 30 other components, climbing...

From looking at the action on Dendreon Corp. (DNDN) shares today, you'd think the company found a cure to cancer. Well . . . not quite, but it may have definitely made a milestone when it comes to cancer therapy. Dendreon reported this morning that its experimental prostate cancer treatment, the...